• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人源化抗血管性血友病因子单克隆抗体AJW200在猴体内的药代动力学和药效学

Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys.

作者信息

Kageyama Shunsuke, Yamamoto Hiroshi, Nakazawa Harumi, Matsushita Junko, Kouyama Tetsuya, Gonsho Akinori, Ikeda Yasuo, Yoshimoto Ryota

机构信息

Developmental Research Laboratories, Pharmaceutical Research Laboratories, Ajinomoto Co, Inc, Kanagawa, Japan.

出版信息

Arterioscler Thromb Vasc Biol. 2002 Jan;22(1):187-92. doi: 10.1161/hq0102.101520.

DOI:10.1161/hq0102.101520
PMID:11788481
Abstract

The interaction between platelet glycoprotein Ib and von Willebrand factor (vWF) plays a crucial role in platelet-mediated thrombus formation under high-shear-stress conditions. The aim of this study was to investigate the antiplatelet profile of a humanized anti-vWF monoclonal antibody, AJW200. In vitro studies were performed with a modified cone-and-plate viscometer and human platelets. AJW200 inhibited high-shear-stress-induced platelet adhesion, aggregation, and thrombin generation, but it did not have such effects under low-shear-stress conditions. Although abciximab inhibited platelet aggregation under both shear stress conditions, it did not inhibit platelet adhesion and thrombin generation. In addition, the pharmacokinetics and pharmacodynamics of AJW200 were evaluated in cynomolgus monkeys. Sustained inhibition of ristocetin-induced platelet aggregation was observed over 24 hours, 6 days, and 2 weeks after a single bolus injection of 0.3, 1, and 3 mg/kg, respectively. Moderate prolongation of the bleeding time was observed at the doses of 1 and 3 mg/kg. Abciximab markedly prolonged the bleeding time at 0.4 mg/kg, at which concentration complete inhibition of ADP-induced platelet aggregation was observed. These results suggest that glycoprotein Ib-vWF blockade with AJW200 results in a sustained antiplatelet effect without extensive prolongation of the bleeding time, probably due to a shear-stress-dependent inhibitory action.

摘要

血小板糖蛋白Ib与血管性血友病因子(vWF)之间的相互作用在高剪切应力条件下血小板介导的血栓形成过程中起着关键作用。本研究的目的是探究人源化抗vWF单克隆抗体AJW200的抗血小板特性。使用改良的锥板粘度计和人血小板进行了体外研究。AJW200抑制了高剪切应力诱导的血小板黏附、聚集和凝血酶生成,但在低剪切应力条件下没有此类作用。尽管阿昔单抗在两种剪切应力条件下均抑制血小板聚集,但它不抑制血小板黏附和凝血酶生成。此外,还在食蟹猴中评估了AJW200的药代动力学和药效学。分别在单次静脉注射0.3、1和3mg/kg后24小时、6天和2周观察到对瑞斯托霉素诱导的血小板聚集的持续抑制。在1和3mg/kg剂量下观察到出血时间适度延长。阿昔单抗在0.4mg/kg时显著延长出血时间,在此浓度下观察到对ADP诱导的血小板聚集的完全抑制。这些结果表明,用AJW200阻断糖蛋白Ib-vWF会导致持续的抗血小板作用,而不会使出血时间过度延长,这可能归因于剪切应力依赖性抑制作用。

相似文献

1
Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys.人源化抗血管性血友病因子单克隆抗体AJW200在猴体内的药代动力学和药效学
Arterioscler Thromb Vasc Biol. 2002 Jan;22(1):187-92. doi: 10.1161/hq0102.101520.
2
Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.抗糖蛋白Ibα单克隆抗体可有效抑制高剪切力下血小板微粒的形成和凝血酶的生成。
Thromb Haemost. 2006 Dec;96(6):774-80.
3
Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin-induced glycoprotein Ib-von Willebrand factor interaction.区分剪切诱导和瑞斯托菌素/蛇毒类凝血酶诱导的糖蛋白Ib-血管性血友病因子相互作用的小鼠抗糖蛋白Ib单克隆抗体的特性分析
Haemostasis. 2000 May-Jun;30(3):139-48. doi: 10.1159/000022536.
4
Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.抗人血管性血友病因子单克隆抗体AJvW-2的抗血栓形成作用及出血风险
Br J Pharmacol. 1997 Sep;122(1):165-71. doi: 10.1038/sj.bjp.0701354.
5
Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis.
Eur J Pharmacol. 2002 May 17;443(1-3):143-9. doi: 10.1016/s0014-2999(02)01590-x.
6
Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.体内阿司匹林、肝素及抗糖蛋白IIb-IIIa单克隆抗体片段在流动条件下对血小板黏附和聚集的实时比较效应。
Circulation. 1995 Mar 1;91(5):1354-62. doi: 10.1161/01.cir.91.5.1354.
7
Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions.瑞斯托霉素依赖而非蛇毒凝血酶原依赖的血管性血友病因子与血小板糖蛋白Ib-IX-V复合物的结合与剪切力依赖的相互作用相关。
Blood. 2001 Jan 1;97(1):162-8. doi: 10.1182/blood.v97.1.162.
8
High shear stress attenuates agonist-induced, glycoprotein IIb/IIIa-mediated platelet aggregation when von Willebrand factor binding to glycoprotein Ib/IX is blocked.当血管性血友病因子与糖蛋白Ib/IX的结合被阻断时,高剪切应力会减弱激动剂诱导的、糖蛋白IIb/IIIa介导的血小板聚集。
Biochem Biophys Res Commun. 1997 Apr 28;233(3):796-800. doi: 10.1006/bbrc.1997.6554.
9
Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glycoprotein Ib or von Willebrand factor.抗血小板糖蛋白Ib或血管性血友病因子单克隆抗体诱导的Fc受体依赖性血小板聚集。
Thromb Haemost. 2001 Apr;85(4):679-85.
10
Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox.响尾蛇毒素(一种来自墨西哥毒蜥毒液的血小板膜糖蛋白Ib拮抗剂)的抗血栓形成作用。
Blood. 1998 Mar 1;91(5):1582-9.

引用本文的文献

1
Novel strategies in antithrombotic therapy: targeting thrombosis while preserving hemostasis.抗血栓治疗的新策略:在保持止血功能的同时靶向血栓形成。
Front Cardiovasc Med. 2023 Oct 23;10:1272971. doi: 10.3389/fcvm.2023.1272971. eCollection 2023.
2
Small interfering RNA-mediated allele-selective silencing of von Willebrand factor in vitro and in vivo.小干扰RNA介导的血管性血友病因子在体外和体内的等位基因选择性沉默
Blood Adv. 2023 Oct 24;7(20):6108-6119. doi: 10.1182/bloodadvances.2023010643.
3
Current concepts and novel targets for antiplatelet therapy.
抗血小板治疗的当前概念和新靶点。
Nat Rev Cardiol. 2023 Sep;20(9):583-599. doi: 10.1038/s41569-023-00854-6. Epub 2023 Apr 4.
4
Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment.缺血性心血管疾病中的新型抗血栓药物:寻找最佳治疗方法的进展
J Cardiovasc Dev Dis. 2022 Nov 16;9(11):397. doi: 10.3390/jcdd9110397.
5
What is the role of Von Willebrand factor in chronic hepatitis B virus infection to hepatocellular carcinoma: a review article.血管性血友病因子在慢性乙型肝炎病毒感染致肝细胞癌中的作用:一篇综述文章
Ther Adv Chronic Dis. 2022 Nov 15;13:20406223221125683. doi: 10.1177/20406223221125683. eCollection 2022.
6
Age-Associated Increase in Thrombogenicity and Its Correlation with von Willebrand Factor.与年龄相关的血栓形成倾向增加及其与血管性血友病因子的相关性。
J Clin Med. 2021 Sep 16;10(18):4190. doi: 10.3390/jcm10184190.
7
Fibrinolysis in Platelet Thrombi.血小板血栓中的纤维蛋白溶解。
Int J Mol Sci. 2021 May 12;22(10):5135. doi: 10.3390/ijms22105135.
8
Activation of von Willebrand factor via mechanical unfolding of its discontinuous autoinhibitory module.通过机械展开其不连续的自动抑制模块来激活血管性血友病因子。
Nat Commun. 2021 Apr 21;12(1):2360. doi: 10.1038/s41467-021-22634-x.
9
Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?靶向肝脏疾病中的血管性血友病因子:一种新的治疗策略?
J Thromb Haemost. 2021 Jun;19(6):1390-1408. doi: 10.1111/jth.15312. Epub 2021 May 3.
10
Therapeutic strategies for thrombosis: new targets and approaches.血栓治疗策略:新靶点和新方法。
Nat Rev Drug Discov. 2020 May;19(5):333-352. doi: 10.1038/s41573-020-0061-0. Epub 2020 Mar 4.